DoW Breast Cancer, Transformative Breast Cancer Consortium Award

General Information Document Type: Grants Notice Funding Opportunity Number: HT942526BCRPTBCCA Funding Opportunity Title: DoW Breast Cancer, Transformative Breast Cancer Consortium Award Opportunity Category: Discretionary Opportunity Category Explanation: Funding Instrument Type: Cooperative Agreement Category of Funding Activity: Science and Technology and other Research and Development Category Explanation: Expected Number of Awards: 1 Assistance Listings: 12.420 -- Military Medical Research and Development Cost Sharing or Matching Requirement: No Version: Synopsis 1 Posted Date: May 04, 2026 Last Updated Date: May 04, 2026 Original Closing Date for Applications: Sep 30, 2026 Current Closing Date for Applications: Sep 30, 2026 Archive Date: Oct 30, 2026 Estimated Total Program Funding: $ 35,000,000 Award Ceiling: $ Award Floor: $ Eligibility Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: Additional Information Agency Name: Defense Health Agency Contracting Activity - DHACA Description: Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium’s collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges. Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal. Link to Additional Information: Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact: eBRAP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org eBRAP Help Desk